Supply Chain Archives
12/11/2025
Setting the Benchmark for Quality in Cell and Gene Therapy Logistics
Quality in cell and gene therapy (CGT) is the foundation that determines whether a therapy reaches a patient intact and effective. As the industry increasingly scales from early development of CGTs to global commercialization, the margin for error narrows as volume and complexity increase. Standards like ISO 21973 provide a framework, but true industry leadership comes from how those standards are applied. In this, Cryoport Systems is setting that benchmark.
11/07/2025
Cryoport Systems Wins “BioServices Innovation of the Year” for Safepak® Soft System 1800
Cryoport Systems is proud to announce that our Safepak® Soft System 1800 has been named BioServices Innovation of the Year by the prestigious BioTech Breakthrough Awards program. This recognition highlights our continued commitment to advancing cryogenic logistics for cell and gene therapy developers through innovation and excellence when it comes to safety and sustainability.
10/22/2025
Beyond the Box: Why Shipping System Qualification Matters in Advanced Therapies
For advanced therapy logistics, quality isn’t limited to what happens inside the manufacturing suite. It extends across the entire supply chain, from packaging and transport to the systems that safeguard material integrity at every handoff. Yet one of the most critical (and often underestimated) steps in ensuring integrity is a shipping system qualification.
10/01/2025
Cryoport Systems Redefines the Global Supply Chain with Launch of New Facility Near Paris, France
Cryoport Systems is thrilled to announce the grand opening of our revolutionary Global Supply Chain Center in Louvre, France. This cutting-edge campus is a one-stop location for end-to-end, temperature-controlled supply chain solutions and is designed to tackle the most complex challenges in the life sciences industry.
09/13/2025
Cryoport Systems Wins Best Cell & Gene Therapy Supplier Award at APCGTEA 2025
Cryoport Systems is proud to announce that we have been awarded Best Cell & Gene Therapy Supplier – Cell Processing Systems at the 2025 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA).
09/10/2025
Scale Smarter: How Global Supply Chain Centers Amplify CGT Program Growth
Cell and gene therapy (CGT) programs are among the most complex and sensitive operations in the life sciences. From cryopreservation and biostorage to logistics and regulatory compliance, every step in the supply chain can influence product integrity, clinical timelines, and the scalability of the program. For program heads as well as clinical and technical operations teams, the challenge becomes bigger than merely moving materials. It quickly becomes a challenge of scaling efficiently while maintaining compliance and supporting growth across a global network.
07/22/2025
What’s Next for the CGT Industry? Mid-Year Check-In from the Leadership Team
We’re halfway through 2025, and the cell and gene therapy (CGT) landscape stands at a crossroads. Innovation continues to advance, yet the infrastructure required to support commercialization remains under pressure. To assess the current state of the industry and what’s ahead, Cryoport Systems gathered candid insights from our internal leaders across functions, from product development and commercial strategy to operations and client engagement.
06/24/2025
When Every Hour Counts: How Cryoport Systems Rapidly Mobilized to Protect INmune Bio’s Critical Clinical Materials
Biopharmaceutical development, particularly for advanced CGTs, relies on a robust infrastructure of logistics, BioServices, and temperature-controlled supply chains to ensure timely and intact delivery of drug products under stringent regulations. INmune Bio Inc. faced a challenge when a sudden biostorage site closure jeopardized a key clinical trial. However, with a strong support network, they turned to established partners like Cryoport Systems to overcome the crisis.
06/19/2025
